Monster Beverage Corp (MNST) Stock Price Today
Key Stats
- $82.55BMarket Cap
- 10,072,885Volume
- Consumer StaplesSector
- $49.9752W High
- $33.1652W Low
- 71 DaysTypical Hold Time
- $80.85BEnterprise Value
- -Div Yield
- -Trading Activity
Track Monster Beverage Corp (MNST) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Monster Beverage Corp has traded between a low of $33.16 and a high of $49.97, highlighting its annual price range. Buy and sell Monster Beverage Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Most Recent News
One sizable IPO, one direct listing, and one SPAC debuted; Oura delays multibillion-dollar IPO.
This week saw the debut of one sizable IPO, one direct listing, and one SPAC, alongside initial filings from three small IPOs, one direct listing, and six SPACs. Notably, Oura postponed its planned multibillion-dollar IPO, marking a significant devel...

Municipal bonds and high-yield muni-bond funds sharply sold off, raising risks and tax concerns.
Municipal bonds experienced a significant selloff over the past month, with high-yield municipal bond closed-end funds (CEFs) yielding over 8% dropping even more sharply. The article highlights data on five top big-yield muni-bond CEFs, focusing part...

Arrowhead's plozasiran shows strong results to challenge Ionis in severe hypertriglyceridemia market
Arrowhead Pharmaceuticals is set to compete with Ionis in treating severe hypertriglyceridemia (sHTG) using plozasiran, which benefits from a $215 million priority review voucher enabling a faster market launch. Phase III trials SHASTA-3 and SHASTA-4...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.